Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism
NCT ID: NCT02095925
Last Updated: 2017-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
900 participants
OBSERVATIONAL
2008-07-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tumor-educated Platelets in Venous Thromboembolism
NCT02739867
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
NCT01602445
Management of Recurrent Venous Thromboembolism During Anticoagulant Treatment in Cancer Patients - a Prospective Cohort Study
NCT05229471
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
NCT07210671
Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients
NCT00199602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cancer patients
Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chemotherapy started no more than 3 months ago or within 7 days after enrollment
* Aged 18 years or older
* Written informed consent
Exclusion Criteria
* Adjuvant chemotherapy (i.e. after surgery with curative intent)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Amsterdam UMC, location VUmc
OTHER
University Medical Center Groningen
OTHER
Slotervaart Hospital
OTHER
Hôpital Louis Mourier
OTHER
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
OTHER
Instituto Nacional de Cancerologia de Mexico
OTHER
Harry R. Buller
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Harry R. Buller
Harry R Büller, MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Harry R Buller, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Louis Mourier
Colombes, Île-de-France Region, France
Hospital D'Annunziata
Chieti, , Italy
Instituto Nacional de Cancerología
Mexico City, , Mexico
Slotervaart hospital
Amsterdam, North Holland, Netherlands
VU medical center
Amsterdam, North Holland, Netherlands
Academic Medical Center
Amsterdam, North Holland, Netherlands
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I, Wilts IT, Twint DC, Porreca E, Arrieta O, Stepanian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen PW, Buller HR. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017 Sep;102(9):1494-1501. doi: 10.3324/haematol.2017.169060. Epub 2017 May 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MICA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.